- Home
- GNLN vs NLSP Comparison
GNLN vs NLSP Comparison
Compare GNLN & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLN
- NLSP
- Stock Information
- Founded
- GNLN 2005
- NLSP 2015
- Country
- GNLN United States
- NLSP Switzerland
- Employees
- GNLN N/A
- NLSP N/A
- Industry
- GNLN Durable Goods
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- GNLN Consumer Discretionary
- NLSP Health Care
- Exchange
- GNLN Nasdaq
- NLSP Nasdaq
- Market Cap
- GNLN 12.9M
- NLSP 12.4M
- IPO Year
- GNLN 2019
- NLSP 2021
- Fundamental
- Price
- GNLN $3.81
- NLSP $2.50
- Analyst Decision
- GNLN
- NLSP
- Analyst Count
- GNLN 0
- NLSP 0
- Target Price
- GNLN N/A
- NLSP N/A
- AVG Volume (30 Days)
- GNLN 2.3M
- NLSP 411.8K
- Earning Date
- GNLN 08-13-2025
- NLSP 07-15-2025
- Dividend Yield
- GNLN N/A
- NLSP N/A
- EPS Growth
- GNLN N/A
- NLSP N/A
- EPS
- GNLN N/A
- NLSP N/A
- Revenue
- GNLN $9,818,000.00
- NLSP N/A
- Revenue This Year
- GNLN $1,541.21
- NLSP N/A
- Revenue Next Year
- GNLN N/A
- NLSP N/A
- P/E Ratio
- GNLN N/A
- NLSP N/A
- Revenue Growth
- GNLN N/A
- NLSP N/A
- 52 Week Low
- GNLN $2.86
- NLSP $1.30
- 52 Week High
- GNLN $16,350.00
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- GNLN 30.25
- NLSP 52.64
- Support Level
- GNLN $3.65
- NLSP $2.16
- Resistance Level
- GNLN $7.47
- NLSP $3.08
- Average True Range (ATR)
- GNLN 1.70
- NLSP 0.24
- MACD
- GNLN 2.20
- NLSP -0.00
- Stochastic Oscillator
- GNLN 11.32
- NLSP 30.21
About GNLN Greenlane Holdings Inc.
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.